CD22 and acute lymphoblastic leukemia: Although the CR rate of ALL in CD19 or CD22 CAR T-cell treatment is as high as 57% to 93%, the relapse rate reaches 14% to 66% (Table 1), which becomes one of the most significant issues limiting CAR T-cell application.